Inhibition of immunoreactive tumor necrosis factor-α by a chimeric antibody in patients infected with human immunodeficiency virus type 1

Journal of Infectious Diseases

Volumn 174, Issue 1, 1996, Pages 63-68

  Walker, Robert E ^a   Spooner, Katherine M ^b   Kelly, Grace ^b   McCloskey, Richard V ^b   Woody, James N ^b   Falloon, Judith ^b   Baseler, Michael ^b   Piscitelli, Stephen C ^b   Davey Jr , Richard T ^b   Polis, Michael A ^b   Kovacs, Joseph A ^b   Masur, Henry ^b   Clifford Lane, H ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; CHIMERIC ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CA2; PENTOXIFYLLINE; STAVUDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 19244364119     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.1.63     Document Type: Article

References (24)

1. Odeh M. The role of tumour necrosis factor-α in acquired immunodeficiency syndrome. J Intern Med 1990;228:549-56.
2. Agostini C, Zambello R, Trentin L, et al. Alveolar macrophages from patients with AIDS and AIDS-related complex constitutively synthesize and release tumor necrosis factor alpha Am Rev Respir Dis 1991;144:195-201.
3. Lähdevirta J, Maury CPJ, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunode-ficiency syndrome. Am J Med 1988;85:289-91.
4. Reddy MM, Sorrell SJ, Lange M, Grieco MH. Tumor necrosis factor and HIV p24 levels in serum of HIV-infected populations. J Acquir Immune Defic Syndr 1988;1:436-40.
5. Poli G, Fauci AS. Cytokine modulation of HIV expression. Semin Immunol 1993;5:165-73.
6. Roux-Lombard P, Madoux C, Cruchaud A, Dayer JM. Purified blood monocytes from HIV-1-infected patients produce high levels of TNF-α and IL-1. Clin Immunol Immunopathol 1989;50:374-84.
7. Aukrust P, Liabakk NB, Müller F, Lien E, Espevik T, Frøland SS. Serum levels of tumor necrosis factor-α (TNFα) and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994;169:420-4.
8. Poli G, Kinter A, Justement JS, et al. Tumor necrosis factor-α functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990;87:782-5.
9. Matsuyama T, Hamamoto Y, Soma GI, Mizuno D, Yamamoto N, Kobayashi N. Cytocidal effect of tumor necrosis factor on cells chronically infected with human immunodeficiency virus (HIV): enhancement of HIV replication. J Virol 1989;63:2504-9.
10. Mellors JW, Griffith BP, Ortiz MA, Landry ML, Ryan JL. Tumor necrosis factor-α/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages. J Infect Dis 1991;163:78-82.
11. Poli G, Kinter AL, Justement JS, Bressler P, Kehrl JH, Fauci AS. Transforming growth factor-β suppresses human immunodeficiency virus expression and replication in infected cells of the monocyte/macrophage lineage. J Exp Med 1991;173:589-97.
12. Grunfeld C, Kotler DP. Pathophysiology of the AIDS wasting syndrome. AIDS Clin Rev 1992;191-224.
13. Israël-Biet D, Cadranel J, Beldjord K, Andrieu JM, Jeffrey A, Even P. Tumor necrosis factor production in HIV-seropositive subjects. J Immunol 1991;147:490-4.
14. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30:1443-53.
15. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis Rheum 1993;36:1681-90.
16. Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease [letter]. Lancet 1993;342:173-4.
17. Hogan MM, Vogel SN. Measurement of tumor necrosis factor alpha and beta. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current protocols in immunology. New York: J Wiley & Sons, 1993:(suppl 7):6.10.1.
18. Garrelds IM, Zijlstra FJ, Tak CJ, Bonta IL, Beckmannl, Ben Efraim S. A comparison between two methods for measuring tumor necrosis factor in biological fluids. Agents Actions 1993;(38 spec no.):C89-91.
19. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
20. Dewar RL, Highbarger HC, Sarmiento MD, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994;170:1172-9.
21. Gunthard HF, Gowland PL, Schupbach J, et al. A phase I/II clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120. J Infect Dis 1994;170:1384-93.
22. Rand KH, Houck H, Ganju A, Babington RG, Elfenbein GJ. Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients. Bone Marrow Transplant 1989;4:679-83.
23. Rand KH, Gibbs K, Derendorf H, Graham-Pole J. Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. J Clin Pharmacol 1991;31:1151-4.
24. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995;332:567-75.